{"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"groups":[{"description":"Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.","id":"BG000","title":"Doxycycline 100 mg po Bid x 12 Months"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"82","value":"65"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"title":"Not hispanic or latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"title":"Unknown/not reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"294","value":"385"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"12"}],"units":"Participants"}]}],"description":"Study participants with predominant cardiac amyloid involvement.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Patients with predominant amyloid cardiomyopathy constituted the \"cardiac group\" (n=12). Serial cardiac biomarkers (BNP, Troponin I) determinations were used to assess the effect of doxycycline on cardiac amyloid disease progression.","title":"Brain Natriuretic Peptide (BNP)","unitOfMeasure":"pg/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.07","value":"0.11"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"12"}],"units":"Participants"}]}],"description":"Study participants with predominant cardiac amyloid involvement.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Patients with predominant amyloid cardiomyopathy constituted the \"cardiac group\" (n=12). Serial cardiac biomarkers (BNP, Troponin I) determinations were used to assess the effect of doxycycline on cardiac amyloid disease progression.","title":"Troponin I","unitOfMeasure":"ng/mL"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"36.5","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}]}],"description":"Study participants with predominant renal amyloid involvement.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Patients with predominant amyloid nephropathy constituted the \"renal group\" (n=10). Serial creatinine clearance and proteinuria were used to assess the effect of doxycycline on renal amyloid disease progression.","title":"Creatinine Clearance (mL/min)","unitOfMeasure":"mL/min"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.15","value":"5.99"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"10"}],"units":"Participants"}]}],"description":"Study participants with predominant renal amyloid involvement.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Patients with predominant amyloid nephropathy constituted the \"renal group\" (n=10). Serial creatinine clearance and proteinuria were used to assess the effect of doxycycline on renal amyloid disease progression.","title":"Proteinuria (g/day)","unitOfMeasure":"g/day"}]}